In clinical terms, increased collagen levels and a more rigid ECM shortened survival and resulted in a negative response to PD-1 inhibition in melanoma patients, which was associated with a decline in the overall CD8+ T cells and an elevation in the depleted CD8+ T-cell subpopulations [242]. The gene discussed is CD8A; the disease is melanoma.